Company Filing History:
Years Active: 2017-2020
Title: The Innovations of Stephan Fricke
Introduction
Stephan Fricke is a notable inventor based in Leipzig, Germany. He has made significant contributions to the field of immunology, particularly in the development of anti-CD4 antibodies. With a total of three patents to his name, Fricke's work focuses on preventing graft-versus-host disease (GVHD), a serious complication that can occur after stem cell or organ transplants.
Latest Patents
Fricke's latest patents include an innovative method for modifying cell grafts containing immune cells. This method involves incubating a cell graft with an anti-CD4 antibody for a duration ranging from one minute to seven days. Following this incubation, unbound antibodies are removed from the graft. The invention also addresses the modification of antibodies that react to the CD4 human leukocyte antigen. The goal is to create anti-CD4 antibodies with fewer potential T-cell epitopes while maintaining their ability to bind to CD4. This includes the use of an anti-human CD4 antibody that comprises a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL). Importantly, the modifications do not affect the specificity and mode of action of the anti-CD4 antibodies.
Career Highlights
Throughout his career, Stephan Fricke has worked with prestigious organizations, including the Fraunhofer Society for the Advancement of Applied Research. His work in these institutions has allowed him to advance his research and contribute to significant innovations in the field of immunology.
Collaborations
Fricke has collaborated with notable colleagues such as Frank Emmrich and Nadja Hilger. These partnerships have played a crucial role in the development of his research and patents.
Conclusion
Stephan Fricke's contributions to the field of immunology through his innovative patents and collaborations highlight his importance as an inventor. His work continues to impact the medical community, particularly in the prevention of graft-versus-host disease.